You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 4695 results
  1. Rapid Prototype Program for Unmanned Aerial Systems to Generate Low-Cost 4th- and 5th- Generation Threat Replication

    SBC: Blue Force Technologies, Inc.            Topic: AF20RDCSO1

    Today’s aerospace industry struggles to rapidly design, experiment, and field novel aerospace and defense capabilities because of the “lock in” business practices of major prime contractors. The rise of computational tools has not shortened design and build timelines over the last 50 years because their use has been offset by a “hard tooling” mindset investing in overly durable and compl ...

    SBIR Phase II 2022 Department of DefenseAir Force
  2. Cartilage Regeneration with Tunable Inflammation Resistance

    SBC: Cytex Therapeutics, Inc.            Topic: R

    Abstract: Femoroacetabular impingement or FAI is a commonly diagnosed condition affecting a younger patient population than the general osteoarthritis (OA) population. Untreated, FAI invariably leads to OA and, ultimately, total hip arthroplasty (THA). The fact that most FAI diagnoses are made in patients under the age of 40, with many in their late teens and twenties, makes FAI all the more clini ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. BioSphincter to Treat Fecal Incontinence. Phase 1/2 Clinical Trial. SBIR Phase IIB

    SBC: CELLF-BIO LLC            Topic: 300

    Project Summary/Abstract:Fecal incontinence (FI), the involuntary soiling of various amounts of liquid and solid stool, is often devastating from a social, psychological, and hygiene perspective. Men and women suffer from FI equally with a range of 2 - 6% in people aged 20 - 30 years. The prevalence increases to over 15% in people older than 70 years1. FI may result from an isolated or combined lo ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Innovative manufacturing research on forming of large light armor alloy sections resistant to blast and penetration

    SBC: CORVID TECHNOLOGIES, LLC            Topic: A09051

    Weldments that join plates of aluminum or steel combat vehicle hulls can be the lowest strength area of the structure and thus provide a decreased level of ballistic protection. To avoid welds, seamless hulls could be formed from thick plate if a suitable manufacturing process is developed. Corvid Technologies, teamed with Concurrent Technologies Corporation (CTC) performed a series of modeling, s ...

    SBIR Phase II 2011 Department of DefenseArmy
  5. Implantable iontophoresis chemotherapy delivery device for direct infusion ofgemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial

    SBC: Focal Medical, Inc.            Topic: 102

    PROJECT SUMMARY Under the parent grant award 2R44CA224460, Advanced Chemotherapy Technologies (ACT) developed an Implantable Iontophoresis Chemotherapy Delivery Device (ACT-IOP-003) that facilitates the infusion of a wide variety of chemotherapy agents directly into the cancer they are intended to treat, thereby minimizing systemic toxic exposure. ACT continues to focus specifically on treating pa ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Objective, MRI biomarkers for pre-symptomatic detection of autism spectrum disorder at 6 months old: commercial software development and optimization

    SBC: PrimeNeuro, Inc.            Topic: 103

    Project Summary Autism Spectrum Disorder (ASD) is a broad diagnosis for a disorder characterized by symptoms affecting repetitive behavior, social communication, and cognitive ability. 1 in 68 children in the US is affected with ASD (Centers for Disease Control and Prevention, 2017) and the likelihood that a child will be affected with ASD is 10 times higher if they have a sibling with ASD. Tradit ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  7. A new epigenetic toolbox for inflammation research and drug discovery

    SBC: Epicypher, Inc.            Topic: NIAID

    PROJECT SUMMARYGene regulation is controlled in part by histone post-translational modifications (PTMs) on nucleosomes. EpiCypher® is developing fully defined recombinant designer nucleosomes (dNucs) carrying specific histone PTMs to enable epigenetics research and drug development. The power of EpiCypher’s dNuc platform comes from its broad chemical diversity. EpiCypher has commercialized rt 1 ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Preclinical characterization of a novel neuropeptide for inducing "on-demand" voiding

    SBC: Dignify Therapeutics LLC            Topic: 105

    PROJECT SUMMARY (ABSTRACT) Spinal cord injury (SCI) affects an estimated 285,000 Americans. Damage to nerves in the spinal cord can result in a loss of voluntary control over bladder and bowel function that often produces both incontinence and retention of urine and stools in the same patient. The standard of care for urine retention is bladder catheterization to void urine, which may produce urin ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Organismal Radioprotection Through Pharmacological Quiescence

    SBC: G1 THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Syndrome (ARS), including a lethal myelosuppression due to the sensitivity of proliferating hematopoietic stem/progenitor cells (HSPCs) to ionizing radiation (IR). No effective therapy exists to mitigate the hematologictoxicities of TBI. Herein G-Zero Therapeutics seeks to further the proprietary development of small molecule inhibitors of cyclin-dependent kina ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Clinical Development of a Therapeutic Agent for COPD

    SBC: BIOMARCK PHARMACEUTICALS, LTD            Topic: NHLBI

    DESCRIPTION (provided by applicant): Hypersecretion of mucus into the respiratory airways is a major contributing factor in several lung diseases, including chronic pulmonary disease (COPD), asthma, cystic fibrosis, allergic rhinitis, and bronchiectasis.Despite the obvious medical importance, there presently are no effective therapies to control excess mucus secretion in these diseases, and very ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government